Boston Scientific’s (BSX) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Boston Scientific (NYSE:BSX) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $121.00 target price on the medical equipment provider’s stock.

Several other research firms have also recently commented on BSX. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Leerink Partners increased their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Barclays increased their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Finally, Evercore ISI dropped their price objective on shares of Boston Scientific from $115.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average target price of $120.71.

Boston Scientific Price Performance

NYSE:BSX opened at $99.20 on Friday. The stock has a market cap of $146.99 billion, a P/E ratio of 59.05, a PEG ratio of 2.35 and a beta of 0.61. Boston Scientific has a one year low of $80.64 and a one year high of $109.50. The company has a fifty day moving average price of $101.29 and a 200 day moving average price of $101.74. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $17,972,457 in the last quarter. 0.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Boston Scientific by 15.4% during the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after acquiring an additional 3,932 shares during the last quarter. MRA Advisory Group bought a new stake in Boston Scientific during the 2nd quarter worth about $273,000. Bank of New Hampshire grew its holdings in Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after acquiring an additional 16,699 shares during the last quarter. NS Partners Ltd grew its holdings in Boston Scientific by 1.6% during the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after acquiring an additional 5,704 shares during the last quarter. Finally, New England Research & Management Inc. bought a new stake in Boston Scientific during the 2nd quarter worth about $1,133,000. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.